Larimar Therapeutics, Inc. - 10-Q Filing

Larimar Therapeutics reports Q3 financial results including research and development, general and administrative, and technical operations expenses.

SEC EDGAR ·

Tickers: $LRMR

Read the full article at SEC EDGAR

More Regulatory news